Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection

被引:56
|
作者
Zhang, Tianyu [1 ]
Zhang, Ming [1 ]
Rosenthal, Ian M. [1 ,2 ]
Grosset, Jacques H. [1 ]
Nuermberger, Eric L. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
BCG; mouse; isoniazid; rifampin; pyrazinamide; ISONIAZID PREVENTIVE THERAPY; MYCOBACTERIUM-TUBERCULOSIS; CORNELL MODEL; CONTAINING REGIMENS; TUBERCLE-BACILLI; RIFAMPIN; MICE; PYRAZINAMIDE; VACCINE; METRONIDAZOLE;
D O I
10.1164/rccm.200905-0795OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale; Regimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9 months long. A 2-month rifampin+ pyrazinamide regimen is no longer recommended. Shorter regimens are highly desirable. Because substituting rifapentine for rifampin in the standard regimen for active tuberculosis halves the treatment duration needed to prevent relapse in mice, we hypothesized daily rifapentine-based regimens could shorten LTBI treatment to 2 months or less. Objectives: To improve an existing model of LTBI chemotherapy and evaluate the efficacy of daily rifapentine-based regimens. Methods: Mice were immunized with a more immunogenic recombinant Bacille Calmette-Guerin strain (rBCG30) and received very low-dose aerosol infection with Mycobacterium tuberculosis to establish a stable lung bacterial burden below 10(4) CFU without drug treatment. Mice received a control (isoniazid alone, rifampin alone, rifampin+isoniazid, rifampin+pyrazinamide) or test (rifapentine alone, rifapentine+isoniazid, rifapentine+pyrazinamide, rifapentine+ isoniazid+pyrazinamide) regimen for 8 weeks. Rifamycin doses were 10 mg/kg/d, analogous to the same human doses. Outcomes were biweekly lung CFU counts and relapse after 4 to 8 weeks of treatment. Measurements and Main Results: M. tuberculosis CFU counts remained stable around 3.65 log(10) in immunized, untreated mice. Isoniazid or rifampin left all or most mice culture-positive at week 8. Rifampin+ isoniazid cured 0 and 53% of mice and rifampin+pyrazinamide cured 47 and 100% of mice in 4 and 8 weeks, respectively. Rifapentine-based regimens were more active than rifampin+isoniazid and indistinguishable from rifampin+pyrazinamide. Conclusions: In this improved murine model of LTBI chemotherapy with very low lung burden, existing regimens were well represented. Daily rifapentine-based regimens were at least as active as rifampin+pyrazinamide, suggesting they could effectively treat LTBI in 6 to 8 weeks.
引用
收藏
页码:1151 / 1157
页数:7
相关论文
共 50 条
  • [1] Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection
    Zhang, Tianyu
    Li, Si-Yang
    Williams, Kathy N.
    Andries, Koen
    Nuermberger, Eric L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (06) : 732 - 737
  • [2] Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
    Croda, Julio
    [J]. REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2015, 48 (05) : 505 - 506
  • [3] Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
    Liou, Bo-Huang
    Cheng, Chih-Ning
    Lin, Ya-Ting
    Lin, Yu-Jou
    Chuang, Yu-Chung
    Lin, Kuan-Yin
    Liu, Wen-Chun
    Lin, Shu-Wen
    Kuo, Ching-Hua
    Sun, Hsin-Yun
    Hung, Chien-Ching
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 (11)
  • [4] Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection
    Cook, Paul P.
    Maldonado, Ricardo A.
    Yarnell, Connie T.
    Holbert, Don
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (03) : 271 - 275
  • [5] Short-Course Isoniazid Plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-Organ Transplant Candidates
    de Castilla, Diego Lopez
    Rakita, Robert M.
    Spitters, Christopher E.
    Narita, Masahiro
    Jain, Rupali
    Limaye, Ajit P.
    [J]. TRANSPLANTATION, 2014, 97 (02) : 206 - 211
  • [6] Trends in tuberculosis clinicians' adoption of short-course regimens for latent tuberculosis infection
    Feng, Pei-Jean I.
    Horne, David J.
    Wortham, Jonathan M.
    Katz, Dolly J.
    [J]. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2023, 33
  • [7] SHORT-COURSE DAILY CHEMOTHERAPY FOR TUBERCULOSIS
    RIEHL, ED
    BEREZNICKI, G
    [J]. PENNSYLVANIA MEDICINE, 1979, 82 (03) : 20 - 23
  • [8] SHORT-COURSE THERAPY FOR TUBERCULOSIS
    AQUINAS, M
    [J]. DRUGS, 1982, 24 (02) : 118 - 132
  • [9] Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study
    Gao, Lei
    Zhang, Haoran
    Xin, Henan
    Liu, Jianmin
    Pan, Shouguo
    Li, Xiangwei
    Guan, Ling
    Shen, Fei
    Liu, Zisen
    Wang, Dakuan
    Guan, Xueling
    Yan, Jiaoxia
    Li, Hengjing
    Feng, Boxuan
    Cao, Xuefang
    Chen, Yu
    Cui, Wei
    Zhang, Zongde
    Ma, Yu
    Chen, Xiaoyou
    Zhou, Xinhua
    Jin, Qi
    Cao, Xuefang
    Feng, Boxuan
    Han, Dongmei
    Li, Hengjing
    Li, Mufei
    Li, Xiangwei
    Li, Yuhui
    Liu, Feng
    Wang, Lingling
    Xin, Henan
    Xiu, Leshan
    Zhang, Chi
    Zhang, Haoran
    Chang, Huilan
    Deng, Yulei
    Dong, Jianhua
    Gao, Fangfang
    Guan, Xueling
    Hu, Zhiti
    Huang, Yuanli
    Kang, Jiling
    Li, Hongzhi
    Li, Quanwei
    Li, Xiaolong
    Lin, Shuang
    Liu, Dongyan
    Liu, Jianmin
    Liu, Pei
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (06)
  • [10] Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection
    Ijaz, Kashef
    McElroy, Peter D.
    Jereb, John
    Navin, Thomas R.
    Castro, Kenneth G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (03) : 464 - 465